Abstract
We report on a series of 24 patients with newly diagnosed mantle cell lymphoma treated with four to six courses of DHAP-rituximab followed by autologous stem cell transplantation for patients <65 years. Three-year overall survival (OS) and event free survival (EFS) rates were 69% and 65% respectively, for the 24 patients. In intent-to-treat analysis, 3-year OS and EFS were 75% and 76% for the 17 patients < 65 years old. This treatment is quite feasible and compares favourably with other regimens.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / therapeutic use
-
Cytarabine / therapeutic use
-
Dexamethasone / therapeutic use
-
Female
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Lymphoma, Mantle-Cell / drug therapy*
-
Lymphoma, Mantle-Cell / mortality
-
Lymphoma, Mantle-Cell / surgery*
-
Male
-
Middle Aged
-
Rituximab
-
Survival Rate
-
Transplantation, Autologous
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Cytarabine
-
Rituximab
-
Dexamethasone
-
Cisplatin